Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study

NCT05862285

RecruitingPhase 3

Sponsor: Hoffmann-La Roche

Conditions: Cancer

Interventions: Ipatasertib, Tiragolumab, Atezolizumab, Tiragolumab and Atezolizumab, Bevacizumab

Countries: Belgium, Canada, China, Costa Rica, France, Greece, Japan, Mexico

The purpose of this extension study is to provide continued treatment with Roche investigational medicinal product (IMP\[s\]) monotherapy or Roche IMP(s) combined with other agent(s) or comparator agent(s) for eligible participants with cancer who are still on study treatment at the time of roll-over from the parent study and who do not have access to the study treatment locally.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Eligible for continuing Roche IMP-based therapy at the time of roll-over from the parent study, as per the parent study protocol OR
* Eligible for continuing the comparator agent(s) in a Genentech- or Roche-sponsored study as per the parent study protocol, with no access to commercially available comparator agent
* First dose of study treatment in this extension study will be received within 7 days of the treatment interruption window allowed by the parent study
* Continue to benefit from the Roche IMP-based therapy or comparator at the time of roll-over from the parent study as assessed by the investigator
* Ability to comply with the extension study protocol, per Investigator's judgement

Exclusion Criteria:

* Meet any of the study treatment discontinuation criteria specified in the parent study at the time of enrollment in this extension study
* Study treatment or comparator agent is commercially marketed in the participant's country for the participant-specific disease and is accessible to the participant
* Treatment with any anti-cancer treatment (other than treatment permitted in the parent study) during the time between last treatment in the parent study and the first dose of study treatment in this extension study
* Permanent discontinuation of all study treatment(s) or comparator agent(s) for any reason during the parent study or during the time between last treatment in the parent study and the first dose of study treatment in this extension study (if applicable)
* Ongoing SAE(s) that has not resolved to baseline level or Grade ≤1 from the parent study or during the time between the last treatment in the parent study and the first dose of study treatment in this extension study
* Concurrent participation in any therapeutic clinical trial (other than the parent study)
Locations (67)
  • Charleroi, Belgium
  • Kortrijk, Belgium
  • Leuven, Belgium
  • Toronto, Ontario, Canada
  • XI 'an City, Shaanxi Province, Shaanxi, China
  • Shanghai, Shanghai Municipality, China
  • Beijing, China
  • Changchun, China
  • Chengdu, China
  • Guangzhou, China
  • Hangzhou, China
  • Hangzhou, China
  • Harbin, China
  • Hefei, China
  • Meizhou, China
  • Nanchang, China
  • Nanjing, China
  • Shanghai, China
  • Shanghai, China
  • Wuhan, China
  • Xiamen, China
  • Xinxiang, China
  • Zhengzhou, China
  • San José, Costa Rica
  • San José, Costa Rica
  • Bordeaux, France
  • Caen, France
  • Dijon, France
  • Lyon, France
  • Marseille, France
  • + 37 more on CT.gov